N. Chauret

发表

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Chun Xing Li, R. Young, S. Charleson, 2005, Bioorganic & medicinal chemistry letters.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

M. D'antoni, S. Day, N. Chauret, 2004 .

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).

R. Zamboni, J. Yergey, L. Favreau, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Hypoxia‐induced down‐regulation of CYP1A1/1A2 and up‐regulation of CYP3A6 involves serum mediators

P. du Souich, V. Pichette, N. Chauret, 2002, British journal of pharmacology.

A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry.

R. Oballa, T. Mauriala, K. Bateman, 2005, Rapid communications in mass spectrometry : RCM.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

M. D'antoni, S. Day, N. Chauret, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.

Y. Leblanc, J. Yergey, J. Silva, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry.

M. Ouellet, K. Bateman, Jennifer L Baker, 2004, Chemical research in toxicology.

In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse.

N. Chauret, D. Nicoll-Griffith, A. Gauthier, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Comparison between two classes of selective EP3 antagonists and their biological activities

C. Li, D. Denis, R. Gordon, 2006 .

Comparison between two classes of selective EP(3) antagonists and their biological activities.

Chun Xing Li, D. Denis, R. Gordon, 2006, Bioorganic & medicinal chemistry letters.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

R. Young, C. Brideau, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.

J. Marois, J. Gauthier, J. Yergey, 1999, Analytical biochemistry.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

R. Young, J. Mancini, D. Nicholson, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

R. Young, J. Mancini, H. Perrier, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.

R. Young, D. Denis, K. Metters, 2003, Bioorganic & medicinal chemistry letters.

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

J. Falgueyret, D. Riendeau, C. Brideau, 2006, Bioorganic & medicinal chemistry letters.

In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

R. Young, R. Zamboni, Y. Aubin, 2007, Bioorganic & medicinal chemistry letters.

Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.

Chun Xing Li, C. Brideau, R. Friesen, 2002, Bioorganic & medicinal chemistry letters.

Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112

J. Yergey, C. Li, L. Trimble, 1997 .

Integrated application of capillary HPLC/continuous-flow liquid secondary ion mass spectrometry to discovery stage metabolism studies.

J. Yergey, Y. Ducharme, L. Trimble, 1995, Analytical chemistry.

Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.

H. Perrier, J. Yergey, J. Silva, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.

R. Young, D. Denis, K. Metters, 2003, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

K. Koeplinger, I. Mcintosh, K. Kassahun, 2011, Drug Metabolism and Disposition.

A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.

Jean-François Truchon, Christopher I Bayly, C. Bayly, 2007, Bioorganic & medicinal chemistry letters.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).

D. Riendeau, R. Young, P. Prasit, 2000, Bioorganic & medicinal chemistry letters.

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

R. Young, D. Denis, S. Kargman, 2007, Journal of medicinal chemistry.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

J. Falgueyret, J. Palmer, M. Venuti, 2008, Bioorganic & medicinal chemistry letters.

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

J. Falgueyret, D. Riendeau, C. Brideau, 1996, Journal of medicinal chemistry.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

R Gordon, D. Riendeau, P. Prasit, 1999, Journal of medicinal chemistry.

A new series of selective COX-2 inhibitors : 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

P. Prasit, C. Brideau, C. Chan, 1997 .

Discovery, biosynthesis, and structure elucidation of metabolites of a doping agent and a direct analogue, tetrahydrogestrinone and gestrinone, using human hepatocytes.

L. Trimble, N. Chauret, Jean-François Lévesque, 2005, Analytical chemistry.

Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.

N. Chauret, D. Nicoll-Griffith, A. Gauthier, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Growth characteristics of Sanguinaria canadensis L. Cell suspensions and immobilized cultures for production of benzophenanthridine alkaloids

J. Archambault, D. Rho, N. Chauret, 1992, Applied Microbiology and Biotechnology.

Fluorimetric detection after liquid chromatographic separation of benzophenanthridine alkaloids obtained from cultured cells

J. Archambault, N. Chauret, 1991 .

Solid-phase extraction and fluorimetric detection of benzophenanthridine alkaloids from Sanguinaria canadensis cell cultures

J. Archambault, D. Rho, N. Chauret, 1990 .

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

N. Chauret, D. Garceau, 2019, Pulmonary pharmacology & therapeutics.

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.

R. Oballa, Qingping Wang, F. Massé, 2009, Bioorganic & medicinal chemistry letters.

Evaluation of VCH-759 monotherapy in hepatitis C infection.

O. Nicolas, J. Bédard, P. Ghali, 2009, Journal of hepatology.

940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS

R. Larouche, C. Cooper, N. Chauret, 2009 .

939 PRECLINICAL PHARMACOKINETIC AND ADME CHARACTERIZATION OF VCH-222, A NOVEL NON-NUCLEOSIDE HCV NS5B POLYMERASE INHIBITOR

L. Ste-Marie, N. Chauret, S. May, 2009 .

854 RESULTS OF A SAFETY, TOLERABILITY AND PHARMACOKINETIC PHASE I STUDY OF VCH-916, A NOVEL POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS

R. Larouche, R. Thibert, N. Chauret, 2008 .

92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

C. Cooper, J. McHutchison, E. Lawitz, 2009 .

In Vitro and In Vivo Mechanistic Studies toward Understanding the Role of 1-Aminobenzotriazole in Rat Drug-Drug Interactions

F. Leblond, V. Pichette, N. Chauret, 2015, Drug Metabolism and Disposition.

High-performance gel permeation chromatographic analysis of immunoglobulin M produced by hybridoma cell culture

J. Côté, J. Archambault, N. Chauret, 1992 .

Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.

B. G. Rao, S. Das, D. Bilimoria, 2017, ACS medicinal chemistry letters.

Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.

B. G. Rao, G. Iyer, L. Chan, 2016, Journal of medicinal chemistry.

Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.

L. Chan, S. Das, Oswy Z. Pereira, 2015, Bioorganic & medicinal chemistry letters.

Effect of polymeric adsorbents on the production of sanguinarine by Papaver somniferum cell cultures

Robert D. Williams, J. Archambault, N. Chauret, 1992, Biotechnology and bioengineering.

Structure–activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP3 antagonists

D. Denis, R. Gordon, R. Zamboni, 2005 .

Selective isolation of in vitro phase II conjugates using a lipophilic anionic exchange solid phase extraction method.

J. Gauthier, S. Gagné, N. Chauret, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

D. Riendeau, C. Brideau, J. Mancini, 2001, Bioorganic & medicinal chemistry letters.

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.

J. Falgueyret, M. Percival, R. Young, 2005, Bioorganic & medicinal chemistry letters.

Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.

H. Perrier, K. Bateman, Y. Girard, 2006, Journal of mass spectrometry : JMS.

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

K. Bateman, R. Lackman, D. Stresser, 2001, Drug metabolism and disposition: the biological fate of chemicals.

In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization.

Chun Xing Li, J. Yergey, J. Silva, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Characterization of indirect photometry for the determination of inorganic anions in natural water by ion chromatography

J. Hubert, N. Chauret, 1989 .

Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective.

N. Chauret, R. Houle, Jean-François Lévesque, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Discovery, biosynthesis, and structure elucidation of new metabolites of norandrostenedione using in vitro systems

Y. Aubin, N. Chauret, Jean-François Lévesque, 2005, Steroids.

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

D. Riendeau, P. Prasit, C. Brideau, 2002, Bioorganic & medicinal chemistry letters.

Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.

J. R. Somoza, C. Bayly, J. Palmer, 2006, Journal of Medicinal Chemistry.

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

L. Chan, S. Das, L. L'Heureux, 2014, ACS medicinal chemistry letters.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

Detection of ginkgolide A in Ginkgo biloba cell cultures

D. Carrier, P. Coulombe, R. Neufeld, 1991, Plant Cell Reports.

Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

R. Young, R. Zamboni, K. Bateman, 2007, Bioorganic & medicinal chemistry letters.

A New Series of Selective COX-2 Inhibitors: 5,6-Diarylthiazolo(3,2-b)( 1,2,4)triazoles.

P. Prasit, C. Brideau, C. Chan, 1997 .

CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humans.

J. Yergey, D. Umbenhauer, S. Grossman, 1993, Drug Metabolism And Disposition.

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

N. Chauret, D. Garceau, 2019, Pulmonary pharmacology & therapeutics.

Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

Serge Léger, F Peter Guengerich, S. Léger, 2002, Biochemistry.

In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.

C. Ramachandran, J. Yergey, N. Chauret, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.

G. Iyer, L. Chan, C. Yannopoulos, 2016, Journal of medicinal chemistry.